Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Celgene Corporation    CELG   US1510201049

CELGENE CORPORATION (CELG)

158
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : to Webcast at Upcoming Investor Conferences and Analyst Day

04/29/2013 | 08:40am US/Eastern

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com. Celgene management will provide an overview of the Company.

Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock Conference at 1:20 p.m. ET.

Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.

Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global Healthcare Conference at 11:30 a.m. ET.

Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's 29th Annual Strategic Decisions Conference at 9:00 a.m. ET.

Additionally, Celgene plans to host an Analyst and Institutional Investor Day on May 6. The presentation will be webcast beginning at 1 p.m. ET and is expected to conclude at 5 p.m.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations


© Business Wire 2013
React to this article
Latest news on CELGENE CORPORATION
1d ago CELGENE : Reports Results from Phase III FIRSTTM Trial
1d ago CELGENE : Acetylon Pharmaceuticals Updates on Phase 2 Study of Ricolinostat in C..
3d ago CELGENE : Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for ..
5d ago CELGENE : Additional Analyses of High-Risk Patients from Phase III Study AML-001..
5d ago CELGENE : New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia ..
5d ago CELGENE : Results from Phase III Study of REVLIMID® Lenalidomide Demonstrating I..
5d ago CELGENE : Combination of ISTODAX® romidepsin and Standard CHOP Demonstrates a Co..
5d ago CELGENE : REVLIMID® Lenalidomide Single-Agent and Combination Studies in Mantle ..
5d ago CELGENE : New Data in Myelodysplastic Syndromes Presented at the 56th American S..
6d ago CELGENE : Results from Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plu..
Advertisement
Chart
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF